[Evaluation of bone loss in patient treated with Gn-Rh analogs].
BACKGROUND
The increasing use of analogs of Gn-RH during treatment of some benign gynaecological diseases, has induced the authors to investigate the principal collateral effects, fixing one's attention on the loss of bony mass.


METHODS
This perspective research has considered 38 patients selected for two diseases "endometriosis" and "uterine fibromyomatosis". The therapy has been effected with triptorelin intramuscularly in a dose of 3.75 mg every 28 days for six months, in all six phials.


RESULTS
After a half-yearly cycle of therapy, the loss of bony mass was valued about 3% medium.


CONCLUSIONS
In the light of other studies too, it was decided to confirm the necessity of associating other medicines able to prevent the side effects caused by their analogs of Gn-RH.
Cassese
E
E
II Cattedra di Clinica Ostetrica e Ginecologica, Seconda Università degli Studi, Napoli.
Piscitelli
V
V
Farzati
A
A
Balbi
G C
GC
Balbi
C
C
D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D004715:Endometriosis / Q000188:drug therapy; D005260:Female; D005350:Fibroma / Q000188:drug therapy; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D013007:Growth Hormone-Releasing Hormone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control; D017329:Triptorelin Pamoate / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy
D017329:Triptorelin Pamoate; D013007:Growth Hormone-Releasing Hormone